Methamphetamine (METH) use and dependence is a serious public health concern with implications across multiple areas from societal impact to burden on psychiatric and medical resources. An estimated 8% of admissions to substance abuse treatment programs are related to stimulants with METH/amphetamine abuse. To date, effective pharmacotherapy options to enhance abstinence have not been identified. The objective of this article is to critically review the literature of METH treatment options. Preclinical research and human research with compounds not yet available commercially in the United States will not be included. A literature review was conducted for research on pharmacological treatments for METH use and addiction. Trial information on the use of sertraline, bupropion, mirtazapine, modafinil, dextroamphetamine, ondansetron, risperidone, aripiprazole, baclofen, and gabapentin was reviewed. Aripiprazole trials appeared in the reviewed literature more frequently than the other medications. Based on the findings of this review, no single medication demonstrated consistent efficacy and each trial contained a variety of methodological limitations.
Substance Abuse and Mental Health Services Administration, Office of Applied Studies. The NSDUH Report: Methamphetamine Use. January 26, 2007; Rockville, MD.
2.
LondonJAUtterGHBattistellaFMethamphetamine use is associated with increased hospital resource consumption among minimally injured trauma patients. J Trauma. 2009;66:485–490.
3.
GawinFHEllinwoodEHJr. Cocaine and other stimulants. Actions, abuse, and treatment. N Engl J Med. 1988;318:1173–1182.
4.
SoraILiBFumushimaSMonoamine transporter as a target molecule for psychostimulants. Int Rev Neurobiol. 2009;85:29–33.
5.
BrownJMHansonGRFleckensteinAE. Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants. J Pharmacol Exp Ther. 2001;296:762–767.
6.
SteinkellnerTFreissmuthMSitteHHThe ugly side of amphetamines: short- and long-term toxicity of 3,4-methylenedioxymethamphetamine (MDMA, ‘Ecstasy’), methamphetamine and D-amphetamine. Biol Chem. 2011;392:103–115.
7.
BortolatoMFrauRPirasAPMethamphetamine induces long-term alterations in reactivity to environmental stimuli: correlation with dopaminergic and serotonergic toxicity. Neurotox Res. 2009;15:232–245.
8.
CadetJLMcCoyMTCaiNSMethamphetamine preconditioning alters midbrain transcriptional responses to methamphetamine-induced injury in the rat striatum. PLoS One. 2009;4:e7812.
9.
KerdsanWThanoiSNudmamud-ThanoiS. Changes in glutamate/NMDA receptor subunit 1 expression in rat brain after acute and subacute exposure to methamphetamine. J Biomed Biotechnol. 2009;2009:329631.
10.
BatkiSLMoonJDelucchiKMethamphetamine quantitative urine concentrations during a controlled trial of fluoxetine treatment. Preliminary analysis. Ann N Y Acad Sci. 2000;909:260–263.
11.
PiaseckiMPSteinagelGMThienhausOJAn exploratory study: the use of paroxetine for methamphetamine craving. J Psychoactive Drugs. 2002;34:301–304.
12.
ShoptawSHuberAPeckJRandomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2006;85:12–18.
13.
ShoptawSHeinzerlingKGRotheram-FullerERandomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2008;96:222–232.
14.
ElkashefAMRawsonRAAndersonALBupropion for the treatment of methamphetamine dependence. Neuropsychopharmacology. 2008;33:1162–1170.
15.
NewtonTFRoacheJDDe La GarzaR 2ndBupropion reduces methamphetamine-induced subjective effects and cue-induced craving. Neuropsychopharmacology. 2006;31:1537–1544.
16.
CruickshankCCMontebelloMEDyerKRA placebo-controlled trial of mirtazapine for the management of methamphetamine withdrawal. Drug Alcohol Rev. 2008;27:326–333.
17.
McGregorCSrisurapanontMMitchellASymptoms and sleep patterns during inpatient treatment of methamphetamine withdrawal: a comparison of mirtazapine and modafinil with treatment as usual. J Subst Abuse Treat. 2008;35:334–342.
18.
HeinzerlingKGSwansonANKimSRandomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2010;109:20–29.
19.
ShearerJDarkeSRodgersCA double-blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence. Addiction. 2009;104:224–233.
20.
LongoMWickesWSmoutMRandomized controlled trial of dexamphetamine maintenance for the treatment of methamphetamine dependence. Addiction. 2010;105:146–154.
21.
GallowayGPBuscemiRCoyleJRA randomized, placebo-controlled trial of sustained-release dextroamphetamine for treatment of methamphetamine addiction. Clin Pharmacol Ther. 2011;89:276–282.
22.
JohnsonBAAit-DaoudNElkashefAMA preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of methamphetamine dependence. Int J Neuropsychopharmacol. 2008;11:1–14.
23.
MeredithCWJaffeCYanasakEAn open-label pilot study of risperidone in the treatment of methamphetamine dependence. J Psychoactive Drugs. 2007;39:167–172.
24.
LileJAStoopsWWVansickelARAripiprazole attenuates the discriminative-stimulus and subject-rated effects of D-amphetamine in humans. Neuropsychopharmacology. 2005;30:2103–2114.
StoopsWW. Aripiprazole as a potential pharmacotherapy for stimulant dependence: human laboratory studies with d-amphetamine. Exp Clin Psychopharmacol. 2006;14:413–421.
27.
StoopsWWLileJAGlaserPEA low dose of aripiprazole attenuates the subject-rated effects of d-amphetamine. Drug Alcohol Depend. 2006;84:206–209.
28.
TiihonenJKuoppasalmiKFohrJA comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence. Am J Psychiatry. 2007;164:160–162.
29.
NewtonTFReidMSDe La GarzaREvaluation of subjective effects of aripiprazole and methamphetamine in methamphetamine-dependent volunteers. Int J Neuropsychopharmacol. 2008;11:1037–1045.
30.
HeinzerlingKGShoptawSPeckJARandomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2006;85:177–184.
